covid-19 pneumonia guidelines

J&J says no evidence darunavir works against coronavirus

Reading now: 414
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Johnson and Johnson (J&J) have noted the lack of evidence that its HIV drug darunavir has antiviral activity against SARS-CoV-2, the novel coronavirus that causes Covid-19.

Currently, HIV protease inhibitors are being considered as potential treatments for the new viral infection. J&J says that the use supports limited, unpublished virologic and clinical data in SARS coronavirus patients.

Darunavir is a protease inhibitor marketed by the company’s unit Janssen Pharmaceutical. The drug has approval as a boosting agent for use in combination with other antiretrovirals to treat HIV-1.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA